AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Home iLIVER Article
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Setting up an integrated service for PSC-IBD patients: A quality improvement project

Sreelakshmi Kotha( )Ioannis KoumoutsosBen WarnerEleni TheocharidouJoel MawdsleyPhilip Berry
Department of Gastroenterology, Guy's and St Thomas' Foundation Trust, London SE1 7EH, United Kingdom
Show Author Information

Abstract

Background and aims

Primary sclerosing cholangitis (PSC) often co-exists with inflammatory bowel disease (IBD) and together they are associated with increased risk of complications, including cancer (hepatobiliary, colorectal, gallbladder) and death. Guidelines for follow up and surveillance vary, but our local guidelines advise annual surveillance with magnetic resonance cholangiopancreatography (MRCP), colonoscopy and ultrasound (US) (6 monthly if cirrhotic). We aimed to assess the quality of care in our PSC-IBD patients, including adherence to local surveillance guidelines, and resultant detection of complications, before and after the introduction of an integrated PSC and IBD out-patient service.

Methods

Data on management of PSC-IBD patients was collected retrospectively before, and prospectively following, the introduction of an integrated service. Descriptive comparisons of diagnoses, adherence to planned surveillance and outcomes were made between cohorts pre- and post-service redesign.

Results

Prior to the service re-design there was significant variability in care and poor adherence to guidelines. Introduction of an integrated PSC-IBD service led to 89 referrals with possible PSC-IBD at 36 months after service re-design. Detailed review led to appropriate identification of 68 PSC-IBD patients. There was significant improvement in surveillance with annual colonoscopy in 90%, MRI/MRCP in 81%, US in 35%, compared to 55%, 55% and 7% respectively in the baseline cohort. This translated to diagnosis and appropriate treatment of colonic dysplasia in 4 patients, colorectal cancer (CRC) in 4 patients and cholangiocarcinoma (CCA) in 2 patients.

Conclusion

Establishment of an integrated out-patient service for PSC-IBD patients results in better compliance with guidelines, effective detection of complications, and appropriate management.

References

[1]

Hirschfield GM, Karlsen TH, Lindor KD, et al. Primary sclerosing cholangitis. Lancet. 2013;382(9904):1587-99. https://doi.org/10.1016/S0140-6736(13)60096-3.

[2]

de Vries AB, Janse M, Blokzijl H, et al. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol 2015;21(6): 1956–71.

[3]

Weismuller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017;152(8):1975-19784 e8.

[4]

Kochhar R, Goenka MK, Das K, et al. Primary sclerosing cholangitis: an experience from India. J Gastroenterol Hepatol 1996;11(5):429-33.

[5]

Takikawa H, Takamori Y, Tanaka A, et al. Analysis of 388 cases of primary sclerosing cholangitis in Japan; Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 2004;29(3):153-9.

[6]

van Munster KN, Bergquist A, Ponsioen CY. Inflammatory bowel disease and primary sclerosing cholangitis: one disease or two? J Hepatol 2024;80(1):155–68. https://doi.org/10.1016/j.jhep.2023.09.031

[7]

Loftus EV, Jr, Harewood GC, Loftus CG, et al. PSC-IBD:a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91-6.

[8]

Boonstra K, van Erpecum KJ, van Nieuwkerk KM, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 2012;18(12):2270-6.

[9]

Sørensen J, Nielsen OH, Andersson M, et al. Inflammatory bowel disease with primary sclerosing cholangitis:a Danish population-based cohort study 1977-2011. Liver Int. 2018;38:532-41.

[10]

Riley TR, Schoen RE, Lee RG, et al. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol. 1997;92:279-82.

[11]

Eliasson J, Lo B, Scramm C, et al. Survey uncovering variations in the management of primary sclerosing cholangitis across Europe. JHEP Rep 2022;4(11):100553.

[12]

Belle A, Laurent V, Pouillon L, et al. Systematic screening for primary sclerosing cholangitis with magnetic resonance cholangiography in inflammatory bowel disease. Dig Liver Dis 2018;50(10):1012-8.

[13]

Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58(6):2045-55.

[14]

Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011;54(5):1842-52.

[15]

Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009;50:158-64.

[16]

Eaton JE, Thackeray EW, Lindor KD. Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol. 2012;107:431-9.

[17]

Zenouzi R, Weismüller TJ, Hübener P, et al. Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol. 2014;12:1733-8.

[18]

Prokopič M, Beuers U. Management of primary sclerosing cholangitis and its complications: an algorithmic approach. Hepatol Int 2021;15(1):6–20. https://doi.org/10.1007/s12072-020-10118-x.

[19]

Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut 2019;68(8):1356–78. https://doi.org/10.1136/gutjnl-2018-317993.

[20]

Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51: 660-78.

[21]

Berry PA, Kotha S. Surveillance imaging in primary sclerosing cholangitis (PSC): evidence, patient preference and physician autonomy. Transl Gastroenterol Hepatol 2022;7:43. https://doi.org/10.21037/tgh-21-87.

[22]

Arndtz K, Hirschfield GM. Primary sclerosing cholangitis and the management of uncertainty and complexity. Frontline Gastroenterol 2017;8(4):260–6. https://doi.org/10.1136/flgastro-2017-100815.

iLIVER
Article number: 100076
Cite this article:
Kotha S, Koumoutsos I, Warner B, et al. Setting up an integrated service for PSC-IBD patients: A quality improvement project. iLIVER, 2024, 3(2): 100076. https://doi.org/10.1016/j.iliver.2024.100076

107

Views

0

Crossref

Altmetrics

Received: 25 September 2023
Revised: 25 December 2023
Accepted: 08 January 2024
Published: 05 February 2024
© 2024 The Author(s). Tsinghua University Press.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return